Improved Open-Access NMR for the Synthetic and Analytical Chemistry Laboratories
Nuclear magnetic resonance spectroscopy is a well-established technique popular for being quantitative by nature and giving unparalleled structural information of both solid and liquid samples. The drawback is that it is perceived as an expensive, difficult to use technique in the hands of few specialists. Due to advances in hardware, software, automation and workflow integration, this is no longer true.
NMR can nowadays be deployed to an open access environment in the chemistry and analytical laboratories. Reduced footprint NMR instruments are no longer installed in the basement, but in any floor, surrounded by other analytical instrumentation, fume cupboards and benches. Improved software makes data acquisition and processing of complex samples and experiments straightforward for even novice users.
What you will discover
In this webinar Dr. Mark Zell, Takeda Pharmaceuticals, and Dr. Anna Codina, Bruker BioSpin, will discuss the benefits of NMR as walk-up instrument in the pharmaceutical industry.
- Examples of NMR instrumentation in walk-up labs
- Applications of the open access NMR for pharmaceutical chemical and analytical R&D
- Benefits and return of investment of the open access NMR
Who should attend?
This webinar will be of interest to those looking to extend and improve their analytical capabilities, heads of medicinal chemistry, analytical and chemical R&D, laboratory managers and expert users of complementary technologies. It is especially dedicated for those seeking to understand the return of investment in NMR in emerging, growing markets.
After her post-doc she worked in the Analytical R&D department of Pfizer, UK, for 8 years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.
She joined Bruker in 2011 as Material Characterisation Laboratory Manager. Since then her role has evolved. She started looking after the pharmaceutical market in 2015 as Product Portfolio Manager. She is now director of the pharmaceutical business Unit at Bruker BioSpin.